Research Article Details
| Article ID: | A23467 |
| PMID: | 23754536 |
| Source: | Mol Med Rep |
| Title: | Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation. |
| Abstract: | Non-alcoholic fatty liver disease (NAFLD) is the most common type of liver disease worldwide. Recent studies have reported that oxymatrine (OMT), an active monomer isolated from Sophora flavescens Ait. (kushen), ameliorates NAFLD in rats. In order to explore the possible molecular mechanism involved, we used an NAFLD rat model with hyperlipidemia, which had been established by feeding a high‑fructose diet (HFD) for eight weeks, and the model rats were subsequently treated with OMT (80 mg/kg/day) for a further four weeks. We evaluated the expression of genes and proteins regulating fatty acid oxidation and lipid export in the liver using quantitative (q)PCR and western blot analysis. The NAFLD model rats developed dyslipidaemia, hepatic steatosis and insulin resistance (IR). OMT administration for four weeks reduced body weight gain and visceral fat weight, decreased serum triglyceride (TG), total cholesterol (TC), free fatty acid (FFA) and fasting serum insulin (FinS) levels and lowered liver TG contents. It also increased the glucose infusion rate (GIR), indicative of a reduction in IR. Moreover, OMT treatment markedly increased the mRNA and protein levels of peroxisome proliferator-activated receptor-α (PPARα), carnitine palmitoyltransferase 1A (CPT1A) and microsomal triglyceride transfer protein (MTTP). The beneficial effects of OMT were further confirmed by the observation of a decrease in lipid accumulation in the histology of the liver. Our results indicate that OMT may be used to treat NAFLD. |
| DOI: | 10.3892/mmr.2013.1512 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D201 | L-Carnitine | Supplement | DB00583 | SLC22A4; SLC22A5; CRAT; MPO | -- | Under clinical trials | Details |
| D142 | Fructose | Chemical drug | DB04173 | -- | Intravenous nutrition drug | Under clinical trials | Details |
| D591 | Matrine | Miscellany | -- | -- | Anti-oxidative stress | Under investigation | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D062 | Carnitine complex | Supplement | DB00583 | SLC22A4; SLC22A5; CRAT; MPO | -- | Under clinical trials | Details |